Medtronic (NYSE:MDT) today announced positive real-world outcomes for thousands of patients using the MiniMed 780G insulin pump system.
Fridley, Minn.-based Medtronic’s MiniMed 780G system automates and personalized the delivery of basal insulin through adjustments every five minutes for 24 hours a day. It includes an advanced algorithm designed to automatically correct highs every five minutes through autocorrelation dosing, while it also protects against lows.
The system currently holds approval for treating type 1 diabetes in people between seven years old and 80 years old to enable the personalization of glucose goals.
Data from real-world clinical observation of 4,120 individuals across nine European countries found an overall time-in-range of 76.2% and an overnight time-in-range of 83%, which mirrors results from the company’s pivotal trial, according to a news release.
Users in the study remained in the advanced hybrid closed loop (AHCL) mode (referred to as the SmartGuard algorithm) for 94% of the time, while the company observed an overall reduction in interactions required with the system, highlighting a potentially more seamless experience than with previous insulin pump systems.
The data aggregates information from patients who uploaded data to the CareLink Personal platform between Aug. 27, 2020, and March 3, 2021. In total, 79% of individuals had a Glucose Management Indicator (GMI) of less than 7%, mirroring the average A1C level expected based on mean glucose.
Additionally, 77.3% of individuals had a time-in-range above 70% and 74.1% of individuals achieved both GMI below 7% and time-in-range above 70%.
“The MiniMed 780G system is doing the job we built it to do – automatically correcting for high glucose when carbs are miscalculated or individuals forget to take extra insulin with their food,” Medtronic EVP & president of its diabetes business Sean Salmon said in the release. “Our goal with all diabetes technology is to maximize clinical outcomes while making the solutions easier to use so that people can feel their best, reduce risk of complications and live their lives with diabetes in the background, instead of the forefront.”